Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Sclerostin negatively regulates bone formation by antagonizing Wnt signalling. An antibody targeting sclerostin for the treatment of postmenopausal osteoporosis was approved by the U.S. Food and Drug Administration, with a boxed warning for cardiovascular risk. Here we demonstrate that sclerostin participates in protecting cardiovascular system and inhibiting bone formation via different loops. Loop3 deficiency by genetic truncation could maintain sclerostin’s protective effect on the cardiovascular system while attenuating its inhibitory effect on bone formation. We identify an aptamer, named aptscl56, which specifically targets sclerostin loop3 and use a modified aptscl56 version, called Apc001PE, as specific in vivo pharmacologic tool to validate the above effect of loop3. Apc001PE has no effect on aortic aneurysm and atherosclerotic development in ApoE−/− mice and hSOSTki.ApoE−/− mice with angiotensin II infusion. Apc001PE can promote bone formation in hSOSTki mice and ovariectomy-induced osteoporotic rats. In summary, sclerostin loop3 cannot participate in protecting the cardiovascular system, but participates in inhibiting bone formation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708322 · Cited by 1,544
Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities
Bäck, M., Yurdagul, A., Tabas, I., Öörni, K., & Kovanen, P. T. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0169-2 · Cited by 1,341
SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor
Semënov, M., Tamai, K., & He, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504308200 · Cited by 771
Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation
Li, D., Liu, J., Guo, B., Liang, C., Dang, L., Lu, C., He, X., Cheung, H. Y.-S., Xu, L., Lu, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10872 · Cited by 588 · cited 6×
“deficient human sclerostin (1-110) knock-in and AngII infusion (Δloop3-SOSTki.”
BackgroundResultInfluentialSelf-citationBovijn, J., Krebs, K., Chen, C.-Y., Boxall, R., Censin, J. C., Ferreira, T., Pulit, S. L., Glastonbury, C. A., Laber, S., Millwood, I. Y., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay6570 · Cited by 119 · cited 6×
“deficient human sclerostin (1-110) knock-in and AngII infusion (Δloop3-SOSTki.”
BackgroundResultInfluential
Cited by
Advancements in tissue engineering for cardiovascular health: a biomedical engineering perspective
Razavi, Z.-S., Soltani, M., Mahmoudvand, G., Farokhi, S., Karimi-Rouzbahani, A., Farasati-Far, B., Tahmasebi-Ghorabi, S., Pazoki-Toroudi, H., & Afkhami, H. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1385124 · Cited by 64
“Most clinical trials that have used bone marrow-derived mononuclear cells (BMMNCs) have demonstrated moderate enhancements in left ventricular function and cardiac perfusion (Cox-Pridmore et al., 2022; Yu et al., 2022).”
BackgroundBone-derived factors mediate crosstalk between skeletal and extra-skeletal organs
He, T., Qin, L., Chen, S., Huo, S., Li, J., Zhang, F., Yi, W., Mei, Y., & Xiao, G. (2025) · Bone Research · doi:10.1038/s41413-025-00424-1 · Cited by 58
“213 One of the genes regulated by SOST is vascular endothelial growth factor (VEGF), a key angiogenic factor.”
Ayaz, A., Zaman, W., Radák, Z., & Gu, Y. (2024) · Antioxidants · doi:10.3390/antiox13040437 · Cited by 26
Bone marrow adipoq+ cell population controls bone mass via sclerostin in mice
Gao, H., Zhong, Y., Lin, S., Yan, Q., Zou, X., & Xiao, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01461-0 · Cited by 19
Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives
Xiaohui, T., Wang, L., Yang, X., Jiang, H., Zhang, N., Zhang, H., Li, D., Li, X., Zhang, Y., Wang, S., et al. (2024) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2024.05.004 · Cited by 10
“Pharmacologic sclerostin loop3 inhibition by therapeutic sclerostin aptamer (Apc001) showed bone anabolic potential for mouse models of Col1a2 + /G610C mice without cardiovascular risk (Tables 1 and 2) [41].”
BackgroundInfluential
Metadata
- Authors
- Yu, Y., Wang, L., Ni, S., Li, D., Liu, J., Chu, H. Y., Zhang, N., Sun, M., Li, N., Ren, Q., Zhuo, Z., Zhong, C., Xie, D., Li, Y., Zhang, Z.-K., Zhang, H., Li, M., Zhang, Z., Chen, L., Pan, X., Xia, W., Zhang, S., Lu, A., Zhang, B.-T., & Zhang, G.
- Venue
- Nature Communications
- Published
- 2022-07-22
- Volume
- 13
- Issue
- 1
- Pages
- 4241-4241
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W4286560124
- Cited by
- 192
- References
- 6
- FWCI
- 40.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation. https://app.cochat.ai/papers/10.1038/s41467-022-31997-8
- The paper
- Yu, Y., Wang, L., Ni, S., Li, D., Liu, J., Chu, H. Y., Zhang, N., Sun, M., Li, N., Ren, Q., Zhuo, Z., Zhong, C., Xie, D., Li, Y., Zhang, Z.-K., Zhang, H., Li, M., Zhang, Z., Chen, L., . . . Zhang, G. (2022). Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation. Nature Communications. https://doi.org/10.1038/s41467-022-31997-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.